Actuate Therapeutics, Inc.

ACTU

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001652935


None

No letter

4 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $14.0M
Warnings	short runway, thin data not computable: degenerate inputs, distress, fortress balance sheet
Inputs computable	4 of 14
Graded from	filings received through Mar 26, 2026 230 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026
Last close	$0.29 2026-11-10; market equity $7.0M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 26, 2026

company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 ("GSK-3"). We are developing elraglusib, an ATP-competitive small molecule that is designed to enter cancer cells and block the function of the enzyme glycogen synthase kinase-3 beta ("GSK-3?"), a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion. We believe that the blockade of GSK-3? signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 16.3						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	(25.9%)	(6.6%)		16.3	800	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 76.1						
Twelve-month failure probability	not computable	0.08%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	(41.61)	(0.35)		86.4	745	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	2.39x	2.95x		65.8	826	2025-12-31
Growth and financing, sleeve percentile 61.4						
Revenue growth, three-year compound	not computable	10.1%				
four annual observations are required; found 0						
Free cash flow growth, three-year compound	not computable	11.0%				
four consecutive annual FCF observations are required; found 0						
Reinvestment rate	not computable	37.1%				
one or more required annual facts are missing						
Asset growth, three years	not computable	2.2%				
four annual observations are required; found 2						
Net share issuance, one year	21.4%	2.5%		61.4	628	2026-03-25

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 2.7 months
Thin data	4 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-10 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(88.3%)	(1.9%)	3
Distance from 52-week high	(96.1%)	(28.5%)	2
EBIT to enterprise value	not computable	(1.6%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	0.14	0.27	32
Sales to price	not computable	0.29	
Composite equity issuance, five years	not computable	20.8%	
Relative strength against the sector, log excess return	(2.31)	(0.19)	3

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$4.4M
Operating cash flow, four quarters	-$19.8M
Months of runway	2.7
Days since last periodic filing	89 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	$202,541

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$22.2M	2025-12-31	2026-03-26	10-K	26-002257
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$19.2M	2025-12-31	2026-03-26	10-K	26-002257
3	assets	us-gaap:Assets	$14.0M	2025-12-31	2026-03-26	10-K	26-002257
4	assets	us-gaap:Assets	$9.3M	2024-12-31	2026-03-26	10-K	26-002257
5	current assets	us-gaap:AssetsCurrent	$13.6M	2025-12-31	2026-03-26	10-K	26-002257
6	current liabilities	us-gaap:LiabilitiesCurrent	$5.7M	2025-12-31	2026-03-26	10-K	26-002257
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$154.6M	2025-12-31	2026-03-26	10-K	26-002257
8	operating income	us-gaap:OperatingIncomeLoss	-$22.5M	2025-12-31	2026-03-26	10-K	26-002257
9	book equity	us-gaap:StockholdersEquity	$7.9M	2025-12-31	2026-03-26	10-K	26-002257
10	liabilities	us-gaap:Liabilities	$6.1M	2025-12-31	2026-03-26	10-K	26-002257
11	shares outstanding	dei:EntityCommonStockSharesOutstanding	23,709,943	2026-03-25	2026-03-26	10-K	26-002257
12	shares outstanding	dei:EntityCommonStockSharesOutstanding	19,531,636	2025-03-10	2025-03-13	10-K	25-001581

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.